

# Roland F Staack

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7359089/roland-f-staack-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

312  
citations

9  
h-index

17  
g-index

24  
ext. papers

389  
ext. citations

2.5  
avg, IF

2.62  
L-index

#	Paper	IF	Citations
20	Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. <i>Bioanalysis</i> , <b>2011</b> , 3, 523-34	2.1	53
19	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). <i>Bioanalysis</i> , <b>2015</b> , 7, 3107-24	2.1	51
18	2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays). <i>Bioanalysis</i> , <b>2017</b> , 9, 1967-1996	2.1	33
17	Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification. <i>Bioanalysis</i> , <b>2012</b> , 4, 381-95	2.1	21
16	Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis. <i>Bioanalysis</i> , <b>2015</b> , 7, 3057-62	2.1	14
15	Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug/biomarker concentrations. <i>Bioanalysis</i> , <b>2014</b> , 6, 485-96	2.1	13
14	Validation of a ligand-binding assay for active protein drug quantification following the Free analyte QC concept. <i>Bioanalysis</i> , <b>2016</b> , 8, 2537-2549	2.1	9
13	Evaluation of the potential use of hybrid LC-MS/MS for active drug quantification applying the Free analyte QC concept. <i>Bioanalysis</i> , <b>2017</b> , 9, 1705-1717	2.1	8
12	Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for active drug. <i>Bioanalysis</i> , <b>2015</b> , 7, 3097-106	2.1	8
11	Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein. <i>Toxicological Sciences</i> , <b>2016</b> , 150, 378-89	4.4	8
10	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (- Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Recommendations). <i>Bioanalysis</i> , <b>2021</b> , 13, 1997-2021	2.1	8
9	How the bioanalytical scientist plays a key role in interdisciplinary project teams in the development of biotherapeutics - a reflection of the European Bioanalysis Forum. <i>Bioanalysis</i> , <b>2014</b> , 6, 1339-48	2.1	7
8	Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. <i>Pharmaceutical Research</i> , <b>2019</b> , 36, 129	4.5	6
7	Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I. <i>Bioanalysis</i> , <b>2016</b> , 8, 2135-45	2.1	6
6	3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis. <i>Bioanalysis</i> , <b>2017</b> , 9, 407-418	2.1	5
5	Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?. <i>Bioanalysis</i> , <b>2020</b> , 12, 1021-1031	2.1	4
4	Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment. <i>AAPS Journal</i> , <b>2015</b> , 17, 1019-24	3.7	2

3	Platform switching from ELISA to Gyrolab® novel generic reagent omits the need to change critical reagents. <i>Bioanalysis</i> , <b>2016</b> , 8, 807-14	2.1	1
2	The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. <i>MAbs</i> , <b>2021</b> , 13, 1995929	6.6	1
1	Increasing robustness, reliability and storage stability of critical reagents by freeze-drying. <i>Bioanalysis</i> , <b>2021</b> , 13, 829-840	2.1	1